RPRX

49.49

0.10% -0.05

Handel nachbörslich: 49.49

Royalty Pharma Plc (RPRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$49.54

Offen:

$49.31

24-Stunden-Volumen:

2.89M

Relative Volume:

0.85

Marktkapitalisierung:

$21.99B

Einnahmen:

$2.38B

Nettoeinkommen (Verlust:

$1.32B

KGV:

27.79

EPS:

1.7806

Netto-Cashflow:

$897.24M

1W Leistung:

-0.46%

1M Leistung:

+6.77%

6M Leistung:

+34.96%

1J Leistung:

+51.30%

1-Tages-Spanne:

$49.21

$50.14

1-Wochen-Bereich:

$49.16

$50.25

52-Wochen-Spanne:

$31.97

$50.25

Royalty Pharma Plc Stock (RPRX) Company Profile

Firmenname

Royalty Pharma Plc

Sektor

Healthcare (1108)

Branche

Biotechnology (620)

Telefon

(212) 883-0200

Adresse

110 EAST 59TH STREET, NEW YORK, NY

Mitarbeiter

100

Twitter

Nächster Verdiensttermin

2026-05-06

Neueste SEC-Einreichungen

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RPRX Royalty Pharma Plc	49.49	22.01B	2.38B	1.32B	897.24M	1.7806
VRTX Vertex Pharmaceuticals Inc	423.24	109.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	686.36	76.72B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	776.02	48.20B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.19	40.31B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	290.80	33.13B	5.36B	287.73M	924.18M	2.5229

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-30	Hochstufung	UBS	Neutral → Buy
2025-09-30	Eingeleitet	Goldman	Buy
2025-05-16	Eingeleitet	Morgan Stanley	Overweight
2024-06-03	Herabstufung	UBS	Buy → Neutral
2022-06-14	Fortgesetzt	UBS	Buy
2022-05-13	Eingeleitet	Scotiabank	Sector Outperform
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-14	Hochstufung	JP Morgan	Neutral → Overweight
2022-04-06	Fortgesetzt	Morgan Stanley	Overweight
2021-10-29	Hochstufung	Citigroup	Neutral → Buy
2021-07-30	Eingeleitet	Tigress Financial	Buy
2020-11-09	Hochstufung	UBS	Neutral → Buy
2020-07-14	Eingeleitet	Evercore ISI	In-line
2020-07-13	Eingeleitet	BofA Securities	Buy
2020-07-13	Eingeleitet	Citigroup	Neutral
2020-07-13	Eingeleitet	Cowen	Outperform
2020-07-13	Eingeleitet	Goldman	Neutral
2020-07-13	Eingeleitet	JP Morgan	Neutral
2020-07-13	Eingeleitet	Morgan Stanley	Equal-Weight
2020-07-13	Eingeleitet	SunTrust	Buy
2020-07-13	Eingeleitet	UBS	Neutral

Alle ansehen

Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten

11:19 AM

Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat

11:19 AM

10:00 AM

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

10:00 AM

06:52 AM

Mitsubishi UFJ Trust & Banking Corp Increases Position in Royalty Pharma PLC $RPRX - MarketBeat

06:52 AM

Apr 28, 2026

Royalty Pharma signs $500M co-development agreement with J&J - MSN

Apr 28, 2026

Affiliate sales disclosed for RPRX (NASDAQ: RPRX) in Form 144 filing - Stock Titan

Apr 28, 2026

Royalty Pharma prices $2B senior unsecured notes - MSN

Apr 28, 2026

Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat

Apr 28, 2026

Royalty Pharma stock hits 52-week high at $50.24 - Investing.com

Apr 28, 2026

Teacher Retirement System of Texas Lowers Position in Royalty Pharma PLC $RPRX - MarketBeat

Apr 28, 2026

Apr 27, 2026

Royalty Pharma declares $0.235 dividend - MSN

Apr 27, 2026

Royalty Pharma in $500M R&D funding collaboration with J&J - MSN

Apr 27, 2026